Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes

University of Colorado Denver (CU Denver)

Status and phase

Withdrawn

Phase 2

Conditions

Type I Diabetes

Treatments

Other: Placebo Comparator

Drug: Anakinra

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT01477476

11-0814

P30DK057516 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This is a randomized, double-blind, placebo-controlled phase 2 study. Specific aim is to evaluate feasibility and safety of anti-IL-1 (interleukin 1) treatment in the course of standard therapy for diabetic ketoacidosis in children and its effect on intracranial pressure.

Full description

Anakinra is a fully human IL-1ra (interleukin 1 receptor agonist) licensed in 2001 by FDA for the treatment of rheumatoid arthritis. It competitively binds to the IL-1 receptor, thus blocking IL-1 signaling. It is a short-acting agent that requires daily subcutaneous administration at 1-2 mg/kg, maximum 100 mg/dose. It has been effective in lowering HbA1c (glycated haemoglobin) in T2D (type 2 diabetes) and a randomized trial of anakinra in recent onset T1D (type 1 diabetes) is underway in Europe. Overall, anakinra has been used in adults and children with a good safety record, for more than 10 years. Infrequent side effects include infections, neutropenia, nausea, diarrhea, cardiopulmonary arrest, influenza-like symptoms, and production of anti-anakinra antibodies.

Study Design: A double-blinded placebo-controlled RCT (randomized controlled trial) with 2:1 allocation (14 active treatment vs. 7 placebo). Anakinra treatment will be given as a bolus of 2 mg/kg infused intravenously over 30 minutes followed by infusion of 2 mg/kg/hour for 4 hours immediately after confirmation of the diagnosis of DKA (diabetic keto-acidosis) and when laboratory safety parameters are available (CBC (complete blood count) and pregnancy test) and after a consent is obtained. Primary outcomes: Safety and tolerability of anti-IL-1 treatment (anakinra) during the initial 24 hr period of DKA treatment. Secondary outcomes: Optic nerve sheath diameter (cut-off to define cerebral edema: 4.5 mm); Changes in cytokines levels during the treatment with anakinra.

Sex

All

Ages

8 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 8-18 years at diagnosis of type 1 diabetes
Diabetic ketoacidosis with:
- plasma glucose concentration >300 mg/dl,
- venous pH <7.30 or
- serum bicarbonate concentration <15 mmol/L, and
- ketones in urine or serum
Hematology:
- WBC >3000 x 109/L;
- platelets >100,000 x 109/L;
- hemoglobin >10.0 g/dL
Negative blood pregnancy test in females.

Exclusion criteria

Children with underlying disorders, including:
- active autoimmune or immune deficiency disorder other than type 1 diabetes,
- malignancy,
- organ transplant,
- any condition requiring chronic corticosteroid use
Previous immunotherapy to prevent type 1 diabetes
Current or prior infection with HIV, hepatitis B or hepatitis C assessed by history
Patients who present with DKA concomitant with alcohol or drug use,
Head trauma,
Meningitis or other conditions which might affect neurological function
Renal failure
Any condition, medical or otherwise that would, in the opinion of the investigator, prevent complete participation in the study, or that would pose a significant hazard to the subject's participation
Patients with a history of known hypersensitivity to:
- E coli-derived proteins,
- anakinra, or
- any components of the investigational drug product